New drug cocktail shows promise against tough lung cancer before surgery
NCT ID NCT07492342
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment approach for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed by surgery. About 30 participants will receive a targeted pill (fulzerasib) for 6 weeks, followed by a short break, then 3 cycles of immunotherapy (sintilimab) plus chemotherapy before their surgery. The goal is to see if this combination can shrink or eliminate the tumor before the operation, potentially improving long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
NOT_YET_RECRUITINGBeijing, China
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
NOT_YET_RECRUITINGZhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
- New targeted pill could boost lung cancer surgery success
- AI model could help doctors predict bladder cancer treatment outcomes